CN119385942A - A kind of nalbuphine hydrochloride injection and preparation method thereof - Google Patents
A kind of nalbuphine hydrochloride injection and preparation method thereof Download PDFInfo
- Publication number
- CN119385942A CN119385942A CN202510012484.XA CN202510012484A CN119385942A CN 119385942 A CN119385942 A CN 119385942A CN 202510012484 A CN202510012484 A CN 202510012484A CN 119385942 A CN119385942 A CN 119385942A
- Authority
- CN
- China
- Prior art keywords
- injection
- citric acid
- sodium citrate
- nalbuphine hydrochloride
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 title claims abstract description 70
- 229960001513 nalbuphine hydrochloride Drugs 0.000 title claims abstract description 57
- 238000002347 injection Methods 0.000 title claims abstract description 47
- 239000007924 injection Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 114
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000001509 sodium citrate Substances 0.000 claims description 37
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000011049 filling Methods 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 239000008215 water for injection Substances 0.000 claims description 16
- 238000007789 sealing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 239000008139 complexing agent Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical group [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 16
- 229960000805 nalbuphine Drugs 0.000 abstract description 12
- 230000009977 dual effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229960004106 citric acid Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 5
- 229960004543 anhydrous citric acid Drugs 0.000 description 5
- 229950004777 sodium calcium edetate Drugs 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of pharmaceutical preparations, and in particular relates to a nalbuphine hydrochloride injection and a preparation method thereof. The invention solves the problem that the impurities of the dual nalbuphine are easy to generate in the prior art by changing the components and the content of the prescription, obviously improves the stability of the preparation and reduces the risks possibly brought by various potential side effects. Meanwhile, the preparation process is optimized, the process time consumption is greatly shortened, and the exposure time of the product is reduced.
Description
Technical Field
The invention belongs to the field of pharmaceutical preparations, and in particular relates to nalbuphine hydrochloride injection and a preparation method thereof.
Background
Nalbuphine is a semisynthetic opioid agonist-antagonist analgesic that is chemically similar to the opioid oxymorphone and the opioid antagonist naloxone. Nalbuphine exhibits both agonism of the opioid kappa receptor and antagonism of the mu receptor. Nalbuphine is administered by intravenous injection, intramuscular injection, subcutaneous injection, and intrathecal administration, and can be used for effectively controlling severe and deep pain caused by heart, lung, abdomen, bone diseases, obstetrical surgery, severe burn, and advanced cancer. The nalbuphine can be used within 2-3 minutes after intravenous administration, and can be used within 15 minutes after intramuscular or subcutaneous injection.
Nalbuphine hydrochloride is white or white-like crystalline powder and is easy to dissolve in water. The prior art describes that nalbuphine hydrochloride injection (trade name: nubain) is stable in a slightly acidic environment, but forms a dual nalbuphine impurity when the pH is raised above 6, and the formation of the impurity is also influenced by light and heavy metal ions, so that the nalbuphine hydrochloride injection loses stability within the shelf life of the medicament.
Patent RU 2254852 (2005.06.27 publication) discloses a nalbuphine injection containing 0.8-2.2. 2.2 wt% nalbuphine hydrochloride, 0.5-3.5 wt% buffer mixture, 0.001-0.2 wt% complexing agent, 0.15-0.25 wt% stabilizer and water for injection. The patent reduces the production of the impurity bisnalbuphine by the addition of complexing agent EDTA, but side effects associated with intravenous EDTA over 5 days may occur, such as hypokalemia, renal and hepatic exacerbation. In addition, such drugs may cause adverse reactions in diabetics, low-potassium patients, heart rate disorder patients and cardiovascular disease patients. RU 2254852 patent specification does not have information about the safety of the proposed drug.
Patent RU 2483731 (2013.06.10 publication) discloses a nalbuphine hydrochloride injection with remarkable analgesic effect, which contains nalbuphine hydrochloride 1.0-2.0 wt%, citric acid 1.26-wt%, sodium citrate 0.94-wt%, sodium chloride 0.1-wt%, sodium metabisulfite 0.1-wt% and water for injection. The injection is added with the antioxidant sodium metabisulfite to improve the stability of the medicine, but is not suitable for asthma patients sensitive to sulfur-containing components.
Based on the problems existing in the prior art, there is still a need for nalbuphine hydrochloride injection with good stability and few side effects, so as to reduce the generation of impurities of the dual nalbuphine, improve the stability of the preparation, and be applicable to various patient groups.
Disclosure of Invention
The invention provides a nalbuphine hydrochloride injection and a preparation method thereof, which solve the technical problem that impurities of the nalbuphine in the prior art are easy to generate, remarkably improve the stability of the preparation and reduce the risks possibly brought by various potential side effects.
The first aspect of the invention provides a nalbuphine hydrochloride injection, which comprises the following components of 5-20 mg nalbuphine hydrochloride, 1.5-7.5 mg sodium chloride, a buffer mixture and water for injection.
The pH value of the injection is about 3.0-4.0.
In some embodiments, each unit of nalbuphine hydrochloride injection comprises 10-20 mg nalbuphine hydrochloride, 2-7 mg sodium chloride, buffer mixture and water for injection.
In some embodiments, each unit of nalbuphine hydrochloride injection comprises 10mg nalbuphine hydrochloride, 4-7.5 mg sodium chloride, buffer mixture and water for injection.
The buffer mixture comprises citric acid and sodium citrate. In some embodiments, the mass ratio of citric acid to sodium citrate is 1:0.55-0.9, preferably the mass ratio of citric acid to sodium citrate is 1:0.65-0.75. In some embodiments, the mass ratio of citric acid to sodium citrate is 1:0.50, 1:0.60, 1:0.65, 1:0.70, 1:0.80, 1:0.85.
In some embodiments, each unit of nalbuphine hydrochloride injection comprises 10-20 mg nalbuphine hydrochloride, 1.5-7.5 mg sodium chloride, citric acid, sodium citrate and water for injection. Further, in some embodiments, each unit of nalbuphine hydrochloride injection comprises 10-20 mg nalbuphine hydrochloride, 2-7 mg sodium chloride, citric acid, sodium citrate and water for injection, wherein the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9, and the preferred mass ratio is 1:0.65-0.75.
In some embodiments, the mass ratio of nalbuphine hydrochloride to citric acid+sodium citrate is about 1:0.35-0.75, preferably about 1:0.45-0.55.
In some embodiments, each unit of nalbuphine hydrochloride injection comprises 10 mg nalbuphine hydrochloride, 4-7.5 mg sodium chloride, citric acid, sodium citrate and water for injection, wherein the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9, preferably 1:0.65-0.7, and the mass ratio of the nalbuphine hydrochloride to the citric acid+sodium citrate in the buffer mixture is about 1:0.35-0.75, preferably about 1:0.45-0.55.
In some embodiments, the nalbuphine hydrochloride injection further comprises a complexing agent, wherein the mass ratio of citric acid to sodium citrate in the complexing agent to the buffer stabilizer is 1:0.005-0.015, and preferably the mass ratio is 1:0.01-0.012.
Preferably, the complexing agent is calcium sodium edetate.
In some embodiments, each unit of the nalbuphine hydrochloride injection comprises 10-20 mg nalbuphine hydrochloride, 1.5-7.5 mg sodium chloride, citric acid, sodium citrate, sodium calcium edetate and water for injection.
Further, in some embodiments, each unit of the nalbuphine hydrochloride injection comprises 10-20 mg parts of nalbuphine hydrochloride, 2-7 mg parts of sodium chloride, citric acid, sodium citrate and calcium sodium edetate, wherein the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9, preferably 1:0.65-0.75, and the mass ratio of the citric acid and the sodium citrate to the calcium sodium edetate is 1:0.005-0.015, preferably 1:0.01-0.012.
In some embodiments, each unit of nalbuphine hydrochloride injection comprises 10mg parts of nalbuphine hydrochloride, 4-7.5 parts of mg parts of sodium chloride, citric acid, sodium citrate, sodium calcium edetate and water for injection, wherein the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9, preferably 1:0.65-0.75, the mass ratio of the nalbuphine hydrochloride to the citric acid+sodium citrate in the buffer mixture is about 1:0.35-0.75, preferably about 1:0.45-0.555, and the mass ratio of the citric acid+sodium citrate to the sodium calcium edetate is about 1:0.005-0.015, preferably 1:0.01-0.012.
The second aspect of the invention provides a preparation method of the nalbuphine hydrochloride injection, which comprises the following steps:
step a, adding water for injection into a liquid preparation tank, adjusting the water temperature, and filling nitrogen;
B, adding auxiliary materials with the prescription amount into a liquid preparation tank, stirring until the auxiliary materials are completely dissolved, and then continuously adding nalbuphine hydrochloride with the prescription amount, stirring until the raw materials are completely dissolved;
c, cleaning, sterilizing and drying the ampoule, filling and sealing, and filling nitrogen before and after filling and sealing;
And d, sterilizing and packaging.
In some embodiments, in the preparation method of the nalbuphine hydrochloride injection, the temperature of the water temperature in the step a is 40-60 ℃.
In some embodiments, in the preparation method of the nalbuphine hydrochloride injection of the present invention, the auxiliary materials in the step b include sodium citrate, anhydrous citric acid and sodium chloride.
In some embodiments, in the preparation method of the nalbuphine hydrochloride injection of the present invention, the auxiliary materials in the step b include sodium citrate, anhydrous citric acid, calcium sodium edetate and sodium chloride.
The invention has the beneficial effects that:
1. the nalbuphine hydrochloride injection has good stability, obviously reduces the content of the dual nalbuphine and obviously inhibits the generation of dual nalbuphine impurities in storage. Meanwhile, the use of sulfur-containing antioxidants and EDTA is avoided, so that various possible side effects can be obviously reduced, and the method is applicable to wider patient population;
2. In the aspect of the preparation process, the preparation process can obviously shorten the process time consumption, reduce the production cost, reduce the exposure time of the product based on the reduction of the process time limit, and reduce the pollution risk of the product on the side surface.
Detailed Description
The present invention is described in further detail below with reference to examples, but is not limited to the following examples, and any equivalents in the art, which are in accordance with the present disclosure, are intended to fall within the scope of the present invention.
In the present application, the terms "comprises," "comprising," and "includes" and their equivalents are to be construed as open, non-exclusive meaning, that "including but not limited to," means that other unspecified elements, components, and steps may be contemplated in addition to those listed. In this document, singular terms encompass plural referents and vice versa, unless the context clearly dictates otherwise.
In the present application, the term "about" means ± 5% based on the original data.
In the present application, pharmaceutical excipients or agents are commercially available.
Examples 1 to 7 contain the following ingredients per unit preparation
The preparation method comprises the following steps:
and a, adding water for injection into a liquid preparation tank, and filling nitrogen.
Adding the sodium citrate, the anhydrous citric acid and the sodium chloride with the prescription amount into a liquid preparation tank, stirring until the auxiliary materials are completely dissolved, continuously adding the nalbuphine hydrochloride with the prescription amount, stirring until the raw materials are completely dissolved, filtering and sterilizing;
c, cleaning, sterilizing and drying the ampoule, filling and sealing, and filling nitrogen before and after filling and sealing;
And d, sterilizing and packaging at the temperature of 121 ℃ for 15min.
The samples of examples 1-7 were tested for pH, with the pH of the sample of example 1 being slightly acidic and the pH of the samples of examples 2 and 7 being approximately 2.8 and 4.2, respectively, and the pH of the products of examples 3-6 being in the range of 3.0-4.0, without the addition of other pH adjusters.
The samples of examples 1 to 7 were left for 6 months at 60.+ -. 2 ℃ to examine the properties and pH changes as follows.
TABLE 1a results of Property changes in samples of examples 1-7
TABLE 1b results of pH changes for examples 1-7 samples
Test results show that the mass ratio of citric acid to sodium citrate is 1:0.55-0.9, and the pH value of the injection can be regulated stably as in examples 3-6, so that the generation of impurities is reduced.
Examples 8-13 contain the following ingredients per unit formulation
Comparative example 1 nalbuphine hydrochloride injection was prepared as described in example 4-1 with reference to RU2254852C 1.
Comparative example 2 nalbuphine hydrochloride injection was prepared as described in example 1 with reference to RU2483731C 1.
The injection samples of examples 8-13 and comparative examples 1-2 were left under light of 4500.+ -.500 lx for 5 days, and were sampled for measurement of pH, content, bisbuprenorphine (P0Z 5) and other related substances, and the mass change of the samples under the above conditions was examined, and the results are shown in Table 2.
Table 2 test results
The inventor finds that the stability of the injection can be obviously improved by adjusting the dosage of citric acid/sodium citrate and adjusting the proportion of nalbuphine hydrochloride to citric acid and sodium citrate, the experiment ensures that the osmotic pressure of each embodiment is consistent by adjusting the dosage of sodium chloride under the condition of keeping the proportion of citric acid and sodium citrate unchanged, the proportion of nalbuphine hydrochloride to citric acid and sodium citrate is changed, and the experiment result shows that the generation of impurities in the nalbuphine hydrochloride injection sample, especially the generation of dual nalbuphine impurities, is easily influenced by illumination, and the stability of the embodiments 8-13 under the illumination condition is obviously improved compared with the comparative examples 1-2.
Examples 14 to 19 contain the following ingredients per unit of preparation
The injectable products of examples 14-19 and comparative examples 1-2 were allowed to stand for 6 months at 60.+ -. 2 ℃ to examine the percentage of the bisbuprenorphine impurity and other impurities, and the results are shown in Table 3a.
Table 3a test results
The injection products of examples 14-19 were left under light 4500.+ -.500 lx for 5 days, and the percentage of the impurities of the bisbuprenorphine (P0Z 5) and other impurities were examined, the results are shown in Table 3b.
Table 3b test results
The test result shows that the stability of the nalbuphine hydrochloride injection under the high-temperature and light conditions can be further improved obviously by further adding the sodium calcium edetate into the prescription and controlling the ratio of the sodium calcium edetate to the citric acid/sodium citrate. The samples of examples 14-19 showed a significant improvement in stability at high temperature and under light conditions, consistent with the pharmaceutical quality requirements, over comparative examples 1-2.
The preparation process according to the prescription composition of examples 16 and 17 is as follows
The preparation process comprises the following steps:
Step a, adding water for injection into 6 liquid preparation tanks respectively, and placing each 2 liquid preparation tanks into 25 ℃ water baths (1-1 batch and 2-1 batch), 40 ℃ water baths (1-2 batch and 2-2 batch) and 60 ℃ water baths (1-3 batch and 2-3 batch) respectively;
Step b, adding sodium citrate, anhydrous citric acid and sodium chloride with the prescription of the example 16 into 1-1 batch, 1-2 batch and 1-3 batch liquid preparation tanks, adding sodium citrate, anhydrous citric acid and sodium chloride with the prescription of the example 17 into 2-1 batch, 2-2 batch and 2-3 batch liquid preparation tanks, stirring until the auxiliary materials are completely dissolved, continuing to add nalbuphine hydrochloride with the corresponding prescription amount, stirring until the raw materials are completely dissolved, recording the dissolution time of the raw materials, reducing the temperature of liquid medicine, and filtering for sterilization;
Step c, cleaning, sterilizing and drying the ampoule, filling and sealing, and filling nitrogen before and after filling and sealing;
and d, sterilizing at 121 ℃ for 15min, and packaging.
The properties, pH, content, and other related substances of each batch of samples were examined, and the results are shown in Table 4a.
Table 4a test results
The test result shows that the dissolution time of the raw materials at 25 ℃ is longer, the liquid preparation temperature is determined to be 40-60 ℃ in consideration of the feasibility of large-scale production, and the production time consumption can be obviously reduced, so that the exposure time of the product is reduced, and the quality of the product meets the requirements.
Secondly, the influence of oxygen on the degradation of the product is examined, namely, the nitrogen filling can reduce the oxygen content in the product and slow down the degradation speed of the product, so that the influence of different nitrogen filling modes of liquid preparation and filling and sealing on the stability of the product is examined. Samples were prepared according to the recipe of examples 16-17, and the preparation method was the same as in example 1 except for the nitrogen dosing mode, which was examined and designed as follows:
Before preparing the liquid, the injection water is filled with nitrogen to below 1.0mg/L, and the liquid medicine is filled with nitrogen to a dissolved oxygen value lower than 1.0mg/L and then encapsulated. And (2) filling nitrogen in the encapsulation, wherein the nitrogen is filled before and after the encapsulation.
The samples are placed at the high temperature of 60 ℃ plus or minus 2 ℃ and are sampled respectively for 0 day and 30 days, the properties, the pH value, the related substances and the content are detected, the headspace residual oxygen is increased for 0 day, and the test results are shown in Table 4b.
Table 4b test results
Test results show that the nitrogen-filled and filled samples of the liquid preparation filling and sealing process are not filled with nitrogen, namely, the nitrogen-filled and filled samples of the liquid preparation filling and sealing process are not filled with nitrogen after being heated for 30 days, the impurity P0Z5 is obviously increased and exceeds the quality standard limit (0.5%), the characters are changed, other detection indexes are not obviously changed, and the nitrogen-filled and filled samples of the liquid preparation filling and sealing process are filled with nitrogen after being mixed liquid preparation filling and sealing process, namely, the impurity P0Z5 is slightly increased and has consistent growing trend after being heated for 30 days.
Those skilled in the art will recognize that the scope of the application is not limited to the various embodiments and examples described above, but is capable of various modifications, substitutions, or rearrangements without departing from the spirit of the application, which are intended to be within the scope of the application.
Claims (9)
1. The nalbuphine hydrochloride injection is characterized by comprising 5-20 mg nalbuphine hydrochloride, 1.5-7.5 mg sodium chloride, a buffer mixture and water for injection, wherein the pH value of the injection is 3.0-4.0, the buffer mixture comprises citric acid and sodium citrate, and the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9.
2. The injection according to claim 1, wherein the mass ratio of nalbuphine hydrochloride to citric acid and sodium citrate is 1:0.35-0.75.
3. The injection according to claim 2, wherein the mass ratio of nalbuphine hydrochloride to citric acid and sodium citrate is 1:0.45-0.55.
4. The injection according to claim 1, wherein each unit of injection comprises 10-20 mg nalbuphine hydrochloride, 2-7 mg sodium chloride, citric acid, sodium citrate and water for injection, wherein the mass ratio of the citric acid to the sodium citrate is 1:0.55-0.9.
5. The injection according to claim 1, further comprising a complexing agent, wherein the complexing agent is edetate sodium calcium.
6. The injection according to claim 5, wherein the mass ratio of citric acid + sodium citrate to complexing agent in the buffer mixture is 1:0.005-0.015.
7. The injection according to claim 6, wherein each unit of injection contains 10-20 mg parts of nalbuphine hydrochloride, 2-7 parts of mg parts of sodium chloride, citric acid, sodium citrate and calcium sodium edetate, wherein the mass ratio of citric acid to sodium citrate is 1:0.55-0.9, the mass ratio of nalbuphine hydrochloride to citric acid and sodium citrate is 1:0.35-0.75, and the mass ratio of citric acid and sodium citrate to complexing agent is 1:0.005-0.015.
8. A process for the preparation of nalbuphine hydrochloride injection as claimed in any one of claims 1 to 7 comprising the steps of:
step a, adding water for injection into a liquid preparation tank, adjusting the water temperature, and filling nitrogen;
B, adding auxiliary materials with the prescription amount into a liquid preparation tank, stirring until the auxiliary materials are completely dissolved, and then continuously adding nalbuphine hydrochloride with the prescription amount, stirring until the raw materials are completely dissolved;
step c, cleaning, sterilizing and drying the ampoule, filling and sealing, and filling nitrogen before and after filling and sealing;
And d, sterilizing and packaging.
9. The method according to claim 8, wherein the water temperature is adjusted to 40-60 ℃ in step a.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510012484.XA CN119385942B (en) | 2025-01-06 | 2025-01-06 | A kind of nalbuphine hydrochloride injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510012484.XA CN119385942B (en) | 2025-01-06 | 2025-01-06 | A kind of nalbuphine hydrochloride injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119385942A true CN119385942A (en) | 2025-02-07 |
| CN119385942B CN119385942B (en) | 2025-03-25 |
Family
ID=94417238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510012484.XA Active CN119385942B (en) | 2025-01-06 | 2025-01-06 | A kind of nalbuphine hydrochloride injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119385942B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113372A1 (en) * | 2001-11-26 | 2003-06-19 | Hu Oliver Yoa-Pu | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same |
| RU2254852C1 (en) * | 2004-01-23 | 2005-06-27 | Ефим Давыдович Нежинский | Injection solution with expressed analgesic effect and method for its preparing |
| RU2483731C1 (en) * | 2012-04-24 | 2013-06-10 | Федеральное государственное унитарное предприятие "Московский эндокринный завод" | Solution for injections containing nalbuphine |
| CN104586755A (en) * | 2014-12-30 | 2015-05-06 | 成都苑东药业有限公司 | Caffeine citrate injection pharmaceutical composition and preparation method thereof |
| CN105440045A (en) * | 2014-08-20 | 2016-03-30 | 宜昌人福药业有限责任公司 | Nalbuphine acidic salt refining technology |
| CN115919858A (en) * | 2022-01-24 | 2023-04-07 | 中国人民解放军总医院第一医学中心 | Analgesic pharmaceutical composition, preparation method and application thereof |
| WO2023150579A2 (en) * | 2022-02-01 | 2023-08-10 | HUMANWELL PHARMACEUTICAL US, Inc. | Pharmaceutical formulations containing nalbuphine |
| CN118903132A (en) * | 2023-05-08 | 2024-11-08 | 苏州恩华生物医药科技有限公司 | Nalbuphine prodrugs and pharmaceutical compositions thereof |
-
2025
- 2025-01-06 CN CN202510012484.XA patent/CN119385942B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113372A1 (en) * | 2001-11-26 | 2003-06-19 | Hu Oliver Yoa-Pu | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same |
| RU2254852C1 (en) * | 2004-01-23 | 2005-06-27 | Ефим Давыдович Нежинский | Injection solution with expressed analgesic effect and method for its preparing |
| RU2483731C1 (en) * | 2012-04-24 | 2013-06-10 | Федеральное государственное унитарное предприятие "Московский эндокринный завод" | Solution for injections containing nalbuphine |
| CN105440045A (en) * | 2014-08-20 | 2016-03-30 | 宜昌人福药业有限责任公司 | Nalbuphine acidic salt refining technology |
| CN104586755A (en) * | 2014-12-30 | 2015-05-06 | 成都苑东药业有限公司 | Caffeine citrate injection pharmaceutical composition and preparation method thereof |
| CN115919858A (en) * | 2022-01-24 | 2023-04-07 | 中国人民解放军总医院第一医学中心 | Analgesic pharmaceutical composition, preparation method and application thereof |
| WO2023150579A2 (en) * | 2022-02-01 | 2023-08-10 | HUMANWELL PHARMACEUTICAL US, Inc. | Pharmaceutical formulations containing nalbuphine |
| CN118903132A (en) * | 2023-05-08 | 2024-11-08 | 苏州恩华生物医药科技有限公司 | Nalbuphine prodrugs and pharmaceutical compositions thereof |
Non-Patent Citations (2)
| Title |
|---|
| VOLODYMYR G TYMKO: "A randomized, double-blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures", 《BRITISH JOURNAL OF CLINICAL PHARMACOLOGY》, vol. 90, no. 7, 22 April 2024 (2024-04-22), pages 1728 - 1740 * |
| 莫静燕: "盐酸纳布啡注射液细菌内毒素检查法研究", 《检验检疫学刊》, vol. 30, no. 4, 28 December 2020 (2020-12-28), pages 43 - 45 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119385942B (en) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4943550B2 (en) | Pharmaceutical composition | |
| WO2012005973A1 (en) | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin | |
| WO2013144814A1 (en) | Stable ready-to-use pharmaceutical composition of pemetrexed | |
| EP3292860A1 (en) | Cabazitaxel fat emulsion injection, and preparation method and use thereof | |
| WO2005092387A1 (en) | Stable injectable diclofenac compositions | |
| CN111374942B (en) | Steroid muscle relaxant injection and preparation method thereof | |
| CN111603439B (en) | Long-acting epipiprazole in-situ phase change gel injection and preparation method thereof | |
| EP3331509B1 (en) | Stable liquid injectable solution of midazolam and pentazocine | |
| CN119385942B (en) | A kind of nalbuphine hydrochloride injection and preparation method thereof | |
| CN119385943A (en) | Phenylephrine hydrochloride injection and its preparation process | |
| CN112438948A (en) | Phloroglucinol composition and preparation method thereof | |
| EP2571498A1 (en) | Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant | |
| CN110123742A (en) | A kind of preparation method of high-quality Plerixafor injection | |
| CN116999403A (en) | Desipramine analogues and oral capsule preparations thereof | |
| CN103830164A (en) | Moxifloxacin hydrochloride injection liquid and preparation method thereof | |
| CN102688185A (en) | Stable palonosetron injection and preparation method thereof | |
| JPH08231403A (en) | Stable aqueous solution containing arginine vasopressin antagonist | |
| US12409155B1 (en) | Ready to use LET formulations | |
| CN101569622B (en) | Pharmaceutical preparation for injection administration and preparation method thereof | |
| AU2022329224B2 (en) | Pharmaceutical composition, preparation method therefor and application thereof | |
| CN114191384A (en) | Instant ketorolac tromethamine and etazocine hydrobromide combined liquid preparation | |
| EP3681473A1 (en) | Topical formulations of chloroprocaine | |
| CN120131542A (en) | A kind of alfentanil hydrochloride injection and preparation method thereof | |
| CN120284864A (en) | Polyoxyethylene 35 castor oil and HS15 solubilized multivitamin injection and preparation method thereof | |
| WO2024151603A1 (en) | Hydromorphone formulations for multi-dose products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |